The Study of the Influence of Pyridine Oxime Derivative (GIZh-298) And Sodium Valproate on the Neurotransmitter Amino Acids Content in the Brain Structures of Mice in the Maximal Electroconvulsive Seizures Test

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

The effect of the antiepileptic compound GIZH-298 and the reference drug sodium valproate (VN) on the content of excitatory and inhibitory amino acids in the frontal cortex, hypothalamus, striatum, and hippocampus of the brain of mice after an electric shock-induced generalized tonic-clonic seizure (MES) was studied. It has been shown that the application of MES reduces the levels of aspartate, glycine, GABA and the ratio of “GABA/glutamate” in the hypothalamus. In the latter, a decrease in the concentration of glutamate, glycine and taurine was noted. VN (200 mg/kg/g) counteracts the effects of MES by interfering with the resulting decrease in GABA and the GABA/glutamate ratio in the hypothalamus. In the hypothalamus, striatum, and hippocampus, VN causes a decrease in the aspartate content both in intact control groups and in the group of mice that received MES. GIZH-298 (60 mg/kg/int. gastric) prevented the MES-induced decrease in the levels of GABA, glycine and taurine and the GABA/glutamate ratio in the hypothalamus.

Texto integral

Acesso é fechado

Sobre autores

V. Narkevich

Federal Research Center for Original and Prospective Biomedical and Pharmaceutical Technologies

Autor responsável pela correspondência
Email: narvik@yandex.ru
Rússia, Moscow

S. Litvinova

Federal Research Center for Original and Prospective Biomedical and Pharmaceutical Technologies

Email: narvik@yandex.ru
Rússia, Moscow

K. Kasabov

Federal Research Center for Original and Prospective Biomedical and Pharmaceutical Technologies; I.M. Sechenov First Moscow state medical University (Sechenov University)

Email: narvik@yandex.ru
Rússia, Moscow; Moscow

A. Yakovleva

Federal Research Center for Original and Prospective Biomedical and Pharmaceutical Technologies

Email: narvik@yandex.ru
Rússia, Moscow

V. Kudrin

Federal Research Center for Original and Prospective Biomedical and Pharmaceutical Technologies

Email: narvik@yandex.ru
Rússia, Moscow

T. Voronina

Federal Research Center for Original and Prospective Biomedical and Pharmaceutical Technologies

Email: narvik@yandex.ru
Rússia, Moscow

Bibliografia

  1. Раевский К.С., Георгиев В.П. // Медиаторные аминокислоты: нейрофармакологические и нейрохимические аспекты. М.: Медицина, 1986. 240 с.
  2. Раевский К.С., Башкатова В.Г., Кудрин В.С., Маликова Л.А., Косачева Е.С., Вицкова Г.Ю., Семиохина А.Ф., Федотова И.Б. // Нейрохимия. 1995. Т. 12. № 4. С. 47—54.
  3. Meldrum B.S. // J. of Nutrition. 2000. V. 130. P. 1007S—1015S.
  4. Platt S. // Vet J. 2007. V. 173. P. 278—286. doi: 10.1016/j.tvjl.2005.11.007.
  5. Wasterlain C.G., Naylor D.E., Liu H., Niquet J., Baldwin R. // Epilepsia. 2013. V. 54. Suppl 6. P. 78—80. doi: 10.1111/epi.12285.
  6. Kapur J. // Epilepsia Open. 2018. V. 3 (Suppl 2). P. 165—168. doi: 10.1002/epi4.12270.
  7. Garrido-Sanabria E.R., Otalora L.F., Arshadmansab M.F., Herrera B., Francisco S., Ermolinsky B.S. // Brain Res. 2008. V. 1240. P. 165—176. doi: 10.1016/j.brainres.2008.08.084.
  8. Bocchio M., Lukacs I., Stacey R., Plaha P., Apostolopoulos V., Livermore L., Sen A., Ansorge O., Gillies M.J., Somogyi P., Capogna M. // Front Cell Neurosci. 2018. V. 12. P. 508. doi: 10.3389/fncel.2018.00508.
  9. Gill D.A., Ramsay S.L., Tasker R.A. // Brain Res. 2010. V. 1331. P. 114—123. doi: 10.1016/j.brainres.2010.03.054.
  10. Воронина Т.А., Гайдуков И.О., Литвинова С.А., Неробкова Л.Н., Жмуренко Л.А. // Фармакокинетика и фармакодинамика. 2016. № 2. С. 37—39.
  11. Гайдуков И.О., Литвинова С.А., Воронина Т.А., Неробкова Л.Н., Жмуренко Л.А., Мокров Г.В., Авакян Г.Г., Кутепова И.С. // Эпилепсия и пароксизмальные состояния. 2017. Т. 9. № 2. С. 57—66.
  12. Литвинова С.А., Кондрахин Е.А., Воронина Т.А., Васильева Е.В., Ковалев Г.И. // Нейрохимия. 2023. Т. 40. № 1. С. 59—67.
  13. Воронина Т.А., Неробкова Л.Н. // Руководство по проведению доклинических исследований лекарственных средств. Под общ. ред. А.Н. Миронова. Ч. 1. М., 2013. C. 235—250.
  14. Pearson S.J., Czudek C., Mercer K., Reynolds G.P. // J. Neuronal. Transm. 1991. V. 86. P. 151—157. doi: 10.1007/BF01250576.
  15. Godin Y., Heiner L., Mark J., Mandel P. // J. Neurochem. 1969. V. 16(3). P. 869—873. doi: 10.1111/j.1471-4159.1969.tb08975.x.
  16. Bruni J., Wilder B. // Arch Neurol. 1979. V. 36 (7). P. 393—398. doi: 10.1001/archneur.1979.00500430023002.
  17. Macdonald R.L., Bergey G.K. // Brain Res. 1979. V. 170(3). P. 558-62. doi: 10.1016/0006-8993(79)90975-2.
  18. Kuanyshbek A., Wang M., Andersson A., Tuifua M., Palmer E., Sachdev R., Mu T.-W., Vetter I., Keramidas A. // Neuropharmacol. 2022. V. 221. P. 109295. doi: 10.1016/j.neuropharm.2022.109295.
  19. Leach M.J., Baxter M.G., Critchley M.A. // Epilepsia. 1991. V. 32. Suppl 2: P. S4-8. doi: 10.1111/j.1528-1157.1991.tb05882.x.
  20. Morland C., Nordengen K., Gundersen V. // Neurosci. Lett. 2012. V. 527. P. 100—104.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Russian Academy of Sciences, 2024